Search research articles
Contact Us
Filters
Showing results (11-20 of 334) with videos related to
Page
of 34
Sort By:
World Journal of Urology
|
November 10, 2019
Developments in oligometastatic hormone-sensitive prostate cancer
Phuoc T Tran, Piet Ost
European Urology
|
November 21, 2019
Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9
Elise De Bleser, Piet Ost
Seminars in Radiation Oncology
|
June 14, 2025
Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer
Maneesh Singh, Vedang Murthy, Piet Ost
JAMA Oncology
|
January 12, 2023
The MIRAGE Trial-Optical Illusion or the Future of Prostate Stereotactic Radiotherapy?
Shankar Siva, Piet Ost, Muhammad Ali
European Urology
|
November 23, 2021
Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
Mathieu Spaas, Nora Sundahl, Piet Ost
European Urology
|
August 2, 2021
Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS
Piet Ost, Shankar Siva, Thomas Zilli
European Urology
|
December 25, 2013
Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-66
Piet Ost, Alberto Briganti, Gianluca Giannarini, et al.
European Urology Focus
|
November 8, 2025
Re: Carlo Andrea Bravi, Sophie Knipper, Axel Heidenreich, et al. Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional Collaboration. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.019
Giulio Francolini, Piet Ost, Thomas Zilli
European Urology
|
February 24, 2018
Is <sup>68</sup>Ga-Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?
Thenappan Chandrasekar, Piet Ost, Derya Tilki
European Urology
|
April 28, 2024
OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
Piet Ost, Shankar Siva, Thomas Zilli
Page
of 34
Search research articles
Search
Showing results (11-20 of 334) with videos related to
Sort By:
Page
of 34
World Journal of Urology
|
November 10, 2019
Developments in oligometastatic hormone-sensitive prostate cancer
Phuoc T Tran, Piet Ost
European Urology
|
November 21, 2019
Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9
Elise De Bleser, Piet Ost
Seminars in Radiation Oncology
|
June 14, 2025
Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer
Maneesh Singh, Vedang Murthy, Piet Ost
JAMA Oncology
|
January 12, 2023
The MIRAGE Trial-Optical Illusion or the Future of Prostate Stereotactic Radiotherapy?
Shankar Siva, Piet Ost, Muhammad Ali
European Urology
|
November 23, 2021
Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
Mathieu Spaas, Nora Sundahl, Piet Ost
European Urology
|
August 2, 2021
Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS
Piet Ost, Shankar Siva, Thomas Zilli
European Urology
|
December 25, 2013
Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-66
Piet Ost, Alberto Briganti, Gianluca Giannarini, et al.
European Urology Focus
|
November 8, 2025
Re: Carlo Andrea Bravi, Sophie Knipper, Axel Heidenreich, et al. Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional Collaboration. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.05.019
Giulio Francolini, Piet Ost, Thomas Zilli
European Urology
|
February 24, 2018
Is <sup>68</sup>Ga-Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?
Thenappan Chandrasekar, Piet Ost, Derya Tilki
European Urology
|
April 28, 2024
OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
Piet Ost, Shankar Siva, Thomas Zilli
Page
of 34